Products Pipeline
Products Pipeline
We have deployed two clinical-stage innovative drugs in the field of oncology. At the same time, we have improved drug targeting and changed drug efficacy and toxicity through ADME improvement and nucleic acid delivery technology.
Oncology
- Project
ResearchPCCINDClinical Phase IClinical Phase IIClinical Phase III
-
LC004B-cell NHL
LC004 belongs to the third generation reversible BTK inhibitor, which has a good inhibitory effect on BTK wild type and C481S mutant, and can solve the problem of BTK C481S mutation resistance. It is intended to be used clinically to treat recurrent/refractory B cell malignant tumors.
-
LC106Pancreatic Cancer
LC106 is a polymer drug loaded anti-tumor system with good tumor permeability and low toxicity. It is intended to be used for the treatment of pancreatic cancer in clinic.
ADME improvement
- Project
ResearchPCCINDClinical Phase IClinical Phase IIClinical Phase III
-
LC201Oral Delivery
-
LC202Transdermal Delivery
Nucleic acid delivery
- Project
ResearchPCCINDClinical Phase IClinical Phase IIClinical Phase III
-
LC301SORT
-
LC302New Transfection
@2022. all rights reserved
About us
